SOLCO
"SOLCO" is a word mark owned by Prinston Pharmaceutical Inc., filed at the USPTO on November 17, 2022. It is registered and covers class 5 (Pharmaceuticals).
- Status
- Registered
- Since March 26, 2024
- Filed
- November 17, 2022
- Registered
- March 26, 2024
- Expires
- Not recorded
- Application no.
- 97681398
- Registration no.
- 7335535
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 1 class
Who owns SOLCO
The owner and representative on file with the office.
Owner
Prinston Pharmaceutical Inc.
Somerset, United States
Representative
Thomas L. Holt
Perkins Coie LLP
What the mark covers
The products and services SOLCO is filed for, grouped by Nice class.
Analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; antimicrobial preservatives for cosmetics and pharmaceuticals; pharmaceutical astringents being astringents for medical purposes; balms for pharmaceutical purposes; cream of tartar for pharmaceutical purposes; creosote for pharmaceutical purposes; dermatological pharmaceutical products; digestives for pharmaceutical purposes; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for pharmaceutical purposes; inhaled pharmaceutical preparations for the treatment of respiratory disease; injectable pharmaceuticals for treatment of anaphylactic reactions; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; iodine for pharmaceutical purposes; liquorice for pharmaceutical purposes; menthol for pharmaceutical purposes; pharmaceutical antitussive-cold preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating hypertension; pharmaceutical products for treating respiratory disease and asthma; pharmaceutical products for the treatment of joint disease; plant extracts for medical, veterinary and pharmaceutical purposes; potassium preparations for pharmaceutical purposes; pharmaceutical preparations and substances for weight loss; vitamin and mineral supplements for use as ingredients in the food and pharmaceutical industry; drug delivery agents in the form of coatings for pills for facilitating the delivery of a wide range of pharmaceuticals; biological preparations for the treatment of cancer and autoimmune deficiencies and disorders; pharmaceutical, veterinary and sanitary preparations, namely, conjugates of organic and inorganic chemicals with polypeptides, proteins, artificial polypeptides, artificial proteins produced by genetic engineering and for the treatment of viral and infectious diseases, immune system disorders, cancer, diabetes, cardiovascular diseases, central nervous system disorders and diseases; anti-diabetic pharmaceuticals; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of registration confirmation emailed
- Registered-principal register
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Teas/email correspondence entered
- Correspondence received in law office
- Teas/email correspondence entered
- Correspondence received in law office
10 earlier steps on the official record.
About SOLCO
Who owns the trademark "SOLCO"?
The USPTO trademark "SOLCO" (application 97681398) is owned by Prinston Pharmaceutical Inc.
What is the status of "SOLCO"?
Its status at the USPTO is: registered.
When was "SOLCO" registered?
It was registered on March 26, 2024.
Get this data via the API
Everything on this page comes from the Signa API. Pull SOLCO and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2b1e-7593-776a-81ec-7339a0a2636d
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2b1e-7593-776a-81ec-7339a0a2636d",
"object": "trademark",
"mark_text": "SOLCO",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "97681398",
"filing_date": "2022-11-17",
"nice_classes": [
5
],
"owners": [
{
"name": "Prinston Pharmaceutical Inc.",
"entity_id": null
}
]
}